Your browser doesn't support javascript.
loading
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Schernthaner, Guntram; Karasik, Avraham; Abraitiene, Agne; Ametov, Alexander S; Gaàl, Zsolt; Gumprecht, Janusz; Janez, Andrej; Kaser, Susanne; Lalic, Katarina; Mankovsky, Boris N; Moshkovich, Evgeny; Past, Marju; Prázný, Martin; Radulian, Gabriela; Smircic Duvnjak, Lea; Tkác, Ivan; Trusinskis, Karlis.
Afiliación
  • Schernthaner G; Medical University of Vienna, Vienna, Austria. guntram.schernthaner@meduniwien.ac.at.
  • Karasik A; Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel. karasik@post.tau.ac.il.
  • Abraitiene A; Clinic of Internal Diseases, Family Medicine and Oncology, Institute of Medicine, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
  • Ametov AS; Russian Medical Academy for Continuous Professional Education, Ministry of Education of the Russian Federation, Moscow, Russia.
  • Gaàl Z; Department of Medicine, András Jósa Teaching Hospital, Nyíregyháza, Hungary.
  • Gumprecht J; Medical University of Silesia, Katowice, Poland.
  • Janez A; Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, Slovenia.
  • Kaser S; Department of Internal Medicine I and CD Laboratory for Metabolic Crosstalk, Medical University of Innsbruck, Innsbruck, Tirol, Austria.
  • Lalic K; Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Mankovsky BN; National Medical Academy for Postgraduate Education, Kiev, Ukraine.
  • Moshkovich E; Diabetes and Endocrinology Clinic, Clalit Medical Services, Ramat Gan, Israel.
  • Past M; Estonian Diabetes Center, Tallinn, Estonia.
  • Prázný M; 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
  • Radulian G; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Smircic Duvnjak L; School of Medicine, University of Zagreb, Vuk Vrhovac University Clinic-UH Merkur, Zagreb, Croatia.
  • Tkác I; Department of Internal Medicine 4, Faculty of Medicine, Safarik University in Kosice, Kosice, Slovakia.
  • Trusinskis K; Latvian Center of Cardiology, Stradins Clinical University Hospital, Riga Stradins University, Riga, Latvia.
Cardiovasc Diabetol ; 18(1): 115, 2019 08 31.
Article en En | MEDLINE | ID: mdl-31472683
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proyectos de Investigación / Compuestos de Bencidrilo / Enfermedades Cardiovasculares / Ensayos Clínicos como Asunto / Medicina Basada en la Evidencia / Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Glucósidos Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cardiovasc Diabetol Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / ENDOCRINOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proyectos de Investigación / Compuestos de Bencidrilo / Enfermedades Cardiovasculares / Ensayos Clínicos como Asunto / Medicina Basada en la Evidencia / Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Glucósidos Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cardiovasc Diabetol Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / ENDOCRINOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido